OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BMND.NLB51

Biomind Labs Inc

Biotechnology & Medical ResearchVerified

Biomind Labs Inc has a highly leveraged capital structure, with total liabilities of $1.71 billion and total equity of -$1.64 billion, resulting in a debt-to-equity ratio of -0.54. The company's liquidity position is weak, as evidenced by a current ratio of 0.03, indicating that it has insufficient current assets to cover its short-term obligations. Operating cash flow is negative at -$115.44 million, and free cash flow is -$183.93 million, further highlighting the company's cash flow challenges. Profitability metrics are concerning, with a net loss of -$186.16 million and an operating loss of -$110.67 million. Return on equity is 11.38%, which is unusually high given the negative equity position, and return on assets is -2.54%, indicating poor asset utilization. These figures suggest the company is not generating sufficient returns to justify its capital structure or asset base. The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns implies a lack of diversification in its revenue streams. This could pose a risk if the company's primary market or product line experiences a downturn. Growth trajectory is not clearly defined in the available data, but the company's negative operating and net income, combined with negative cash flows, suggest a lack of sustainable growth. The outlook for the current fiscal year is likely to remain challenging unless the company can significantly improve its operational performance or secure additional financing. Risk factors include liquidity constraints and the potential for further dilution if the company needs to raise additional capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag. The company's reliance on external financing and its inability to generate positive cash flows increase the risk of financial distress. Recent events, including the latest financial filing, highlight the company's ongoing financial challenges. The absence of recent earnings call transcripts or significant news events suggests a lack of public communication about strategic initiatives or financial improvements.

30-day price · BMND.NLB+0.04 (+21.1%)
Low$0.09High$0.28Close$0.23As of30 May, 00:00 UTC
Profile
CompanyBiomind Labs Inc
TickerBMND.NLB
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

Biomind Labs Inc has a highly leveraged capital structure, with total liabilities of $1.71 billion and total equity of -$1.64 billion, resulting in a debt-to-equity ratio of -0.54. The company's liquidity position is weak, as evidenced by a current ratio of 0.03, indicating that it has insufficient current assets to cover its short-term obligations. Operating cash flow is negative at -$115.44 million, and free cash flow is -$183.93 million, further highlighting the company's cash flow challenges. Profitability metrics are concerning, with a net loss of -$186.16 million and an operating loss of -$110.67 million. Return on equity is 11.38%, which is unusually high given the negative equity position, and return on assets is -2.54%, indicating poor asset utilization. These figures suggest the company is not generating sufficient returns to justify its capital structure or asset base. The company's revenue concentration is not disclosed in the available data, but the absence of segment or geographic breakdowns implies a lack of diversification in its revenue streams. This could pose a risk if the company's primary market or product line experiences a downturn. Growth trajectory is not clearly defined in the available data, but the company's negative operating and net income, combined with negative cash flows, suggest a lack of sustainable growth. The outlook for the current fiscal year is likely to remain challenging unless the company can significantly improve its operational performance or secure additional financing. Risk factors include liquidity constraints and the potential for further dilution if the company needs to raise additional capital. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag. The company's reliance on external financing and its inability to generate positive cash flows increase the risk of financial distress. Recent events, including the latest financial filing, highlight the company's ongoing financial challenges. The absence of recent earnings call transcripts or significant news events suggests a lack of public communication about strategic initiatives or financial improvements.
Key takeaways
  • Biomind Labs Inc is operating at a significant loss, with a net income of -$186.16 million and an operating loss of -$110.67 million.
  • The company's liquidity position is weak, with a current ratio of 0.03 and negative operating and free cash flows.
  • Return on equity is unusually high at 11.38%, but this is due to the negative equity position, and return on assets is -2.54%.
  • The company's capital structure is highly leveraged, with total liabilities of $1.71 billion and total equity of -$1.64 billion.
  • The company's financial health is at risk due to its negative net cash position after subtracting total debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue
Gross profit
Operating income-$110.7k
Net income-$186.2k
R&D
SG&A
D&A
SBC
Operating cash flow-$115.4k
CapEx
Free cash flow-$183.9k
Total assets$73.3k
Total liabilities$1.7M
Total equity-$1.6M
Cash & equivalents
Long-term debt$883.4k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4-$4.3M-$4.3M-$4.3M
FY-3-$2.9M-$3.0M-$2.9M
FY-2-$991.4k-$1.2M-$1.2M
FY-1-$260.5k-$260.5k-$251.6k
FY0-$846.6k-$850.4k-$848.2k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$2.5M$2.2M$2.3M
FY-3$89.1k-$247.7k$26.2k
FY-2$74.2k-$1.4M
FY-1$41.2k-$1.3M
FY0$40.00-$1.7M
PeriodOCFCapExFCFSBC
FY-4-$2.1M-$44.6k-$4.3M
FY-3-$2.2M$0.00-$2.9M
FY-2-$765.9k-$1.2M
FY-1-$354.4k-$251.6k
FY0-$67.5k-$848.2k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7-$110.7k-$186.2k-$183.9k
FQ-6-$108.5k-$212.1k-$209.8k
FQ-5$48.6k-$34.5k-$32.3k
FQ-4-$89.8k$172.3k$174.5k
FQ-3-$115.2k-$66.8k-$64.5k
FQ-2-$92.5k-$116.5k-$116.5k
FQ-1-$87.0k-$102.8k-$102.8k
FQ0-$551.9k-$564.4k-$564.4k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$73.3k-$1.6M
FQ-6$57.8k-$1.8M
FQ-5$53.4k-$1.5M
FQ-4$41.2k-$1.3M
FQ-3$21.1k-$1.4M
FQ-2$21.2k-$1.5M
FQ-1$57.7k-$1.6M
FQ0$40.00-$1.7M
PeriodOCFCapExFCFSBC
FQ-7-$115.4k-$183.9k
FQ-6-$140.6k-$209.8k
FQ-5-$251.7k-$32.3k
FQ-4-$354.4k$174.5k
FQ-3$460.00-$64.5k
FQ-2$20.1k-$116.5k
FQ-1-$18.6k-$102.8k
FQ0-$67.5k-$564.4k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$1.6M
Net cash-$883.4k
Current ratio0.0
Debt/Equity-0.5
ROA-2.5%
ROE11.4%
Cash conversion62.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricBMND.NLBActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity-54.0%1.2% medp25 0.0% · p75 17.4%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-02 02:48 UTC#aaceaf26
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 12:57 UTCJob: 399c4992